Purpose

This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Signed informed consent. - Positive test for COVID-19 and progressive disease suggestive of ongoing COVID-19 infection. - Symptoms of COVID-19 for ≤ 12 days. - Require admission to hospital for acute medical care (not for purely public health or quarantine purposes).

Exclusion Criteria

  • Patients who have received plasma from a person who recovered from COVID-19 or who have received neutralizing monoclonal antibodies at any time prior to hospitalization. - Patients not willing to abstain from participation in other COVID-19 treatment trials until after Day 5 of the study. Co-enrollment in certain trials that compare recommended Standard of Care treatments may be allowed, based on the opinion of the study leadership team. - Any condition which, in the opinion of the responsible investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments. - Patients considered unable to participate in study procedures. - Women of child-bearing potential who are not already pregnant at study entry and who are unwilling to acknowledge strong advice to abstain from sexual intercourse with men or practice appropriate contraception through 18 months of the study. - Women of child-bearing potential who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with men or practice appropriate contraception through 5 weeks of the study (PF-07304814 investigational agent). - Pregnant women (PF-07304814 investigational agents). - Nursing mothers (PF-07304814 investigational agents). - Men who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through 18 months of the study. - Men who are unwilling to acknowledge the strong advice to abstain from sexual intercourse with women of child-bearing potential or to use barrier contraception through 5 weeks of the study (PF-07304814 investigational agent). - Presence at study enrollment of any of the following: 1. stroke 2. meningitis 3. encephalitis 4. myelitis 5. myocardial ischemia 6. myocarditis 7. pericarditis 8. symptomatic congestive heart failure 9. arterial or deep venous thrombosis or pulmonary embolism - Current or imminent requirement for any of the following: 1. invasive mechanical ventilation 2. ECMO (extracorporeal membrane oxygenation) 3. Mechanical circulatory support 4. vasopressor therapy 5. commencement of renal replacement therapy at this admission (i.e. not patients on chronic renal replacement therapy). - Participants with moderate to severe hepatic impairment (i.e. Child-Pugh class B or C) or acute liver failure (PF-07304814 investigational agent). - Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 (PF-07304814 investigational agent). - Patients will be excluded if taking drugs which have a narrow therapeutic window that are substrates of CYP3A4, including but not limited to: astemizole, cisapride, cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, tacrolimus, and terfenadine (PF-07304814 investigational agent). - Patients with a history of deep vein thrombosis or pulmonary thrombotic embolism (Prior to initial futility assessment of PF-07304814 investigational agent).

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
ACTIV-3 Drug plus SOC
Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC
  • Biological: LY3819253
    Participants are no longer being randomized to this intervention.
  • Biological: Remdesivir
    Provided to all study participants as SOC unless contraindicated for an individual patient.
  • Biological: VIR-7831
    Participants are no longer being randomized to this intervention.
  • Biological: BRII-196/BRII-198
    Participants are no longer being randomized to this intervention.
  • Biological: AZD7442
    Participants are no longer being randomized to this intervention.
    Other names:
    • AZD8895 + AZD1061
  • Drug: MP0420
    Participants are no longer being randomized to this intervention.
    Other names:
    • ensovibep
  • Drug: PF-07304814
    250 mg per day for 5 days. Administered as a constant rate intravenous infusion
Placebo Comparator
Placebo plus SOC
The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
  • Drug: Placebo
    Commercially available 0.9% sodium chloride solution. Administered by IV infusion
  • Biological: Remdesivir
    Provided to all study participants as SOC unless contraindicated for an individual patient.

Recruiting Locations

Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue
Tucson, Arizona 85719
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Southern Arizona VA Healthcare System (Site 074-009), 3601 S. 6th Ave.
Tucson, Arizona 85723
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email, and send to
ticova@insight-trials.org

Velocity Chula Vista (Site 080-034), 752 Medical Center Ct., Ste. 304
Chula Vista, California 91911
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Community Regional Medical Center (Site 203-005), 2823 Fresno Street
Fresno, California 93701
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Velocity San Diego (Site 080-035), 5565 Grossmont Center Drive, Building 2, Suite 1
La Mesa, California 91942
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street
Loma Linda, California 92357
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

VA Long Beach Healthcare System (Site 074-026), 5901 East 7th Street (09/151-M2)
Long Beach, California 90822
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

Keck Hospital of USC (Site 301-020), 1500 San Pablo Street
Los Angeles, California 90033
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd.
Los Angeles, California 90048
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza
Los Angeles, California 90095
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Sacramento VA Medical Center (Site 074-023), 10535 Hospital Way
Mather, California 95655
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

Hoag Memorial Hospital Presbyterian (Site 080-026), One Hoag Drive
Newport Beach, California 92663
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Palo Alto VAMC (Site 074-005), 3801 Miranda Avenue
Palo Alto, California 94304
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

VA San Diego Healthcare System (Site 074-016), 3350 La Jolla Village Drive
San Diego, California 92161
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St.
San Francisco, California 94115
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

San Francisco VAMC (Site 074-002), 4150 Clement St.
San Francisco, California 94121
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

UCSF Medical Center (Site 203-001), Moffitt-Long Hospital, 505 Parnassus Ave.
San Francisco, California 94143
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr.
Stanford, California 94305
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson Street, CDCRC Building
Torrance, California 90502
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue
Aurora, Colorado 80045
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Denver Public Health (Site 017-004), 660 Bannock St., MC2600 (Infectious Disease Clinic)
Denver, Colorado 80204
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

National Jewish Health / St. Joseph Hospital (Site 204-003), 1400 Jackson Street
Denver, Colorado 80206
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email, and send to
ticopetal@insight-trials.org

West Haven VA Medical Center (Site 025-007), 950 Campbell Avenue
West Haven, Connecticut 06516
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

MedStar Health Research Institute (Site 009-021), MedStar Washington Hospital Center, 110 Irving St., NW.
Washington, District of Columbia 20010
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Washington DC VA Medical Center (Site 009-004), 50 Irving Street NW
Washington, District of Columbia 20422
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Bay Pines VAMC (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104
Bay Pines, Florida 33744
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

Baycare Health System (Site 301-025), Morton Plant Hospital, 300 Pinellas Street
Clearwater, Florida 33756
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

North Florida/South Georgia Veterans Health System (Site 074-011), 1601 SW. Archer Road
Gainesville, Florida 32608-1197
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

Memorial Healthcare System (Site 648-002), Memorial Regional Hospital, 3501 Johnson Street
Hollywood, Florida 33021
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Miami VAMC (Site 074-003), 1201 NW 16 Street
Miami, Florida 33125
Contact:
If interested in participating at this site, enter site name and ACITV-3 in subject line of email and send to
ticova@insight-trials.org

Hillsborough County Health Department, University of South Florida (Site 032-001)
Tampa, Florida 33602
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Emory University (Site 301-008), The Emory Clinic, Bldg. A, Suite 2236, 1365 Clifton Rd., NE
Atlanta, Georgia 30322
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard
Fort Wayne, Indiana 46804
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Cotton O'Neil Clinical Research Center (Site 080-030), Stormont Vail Health, 1500 SW 10th Avenue
Topeka, Kansas 66604
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

University of Kentucky Hospital (Site 210-004), 1000 South Limestone St.
Lexington, Kentucky 40536
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway
New Orleans, Louisiana 70121
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

University of Maryland Medical Center (Site 301-019), 22 South Greene Street
Baltimore, Maryland 21201
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Massachusetts General Hospital (Site 202-002), 55 Fruit Street
Boston, Massachusetts 02114
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Beth Israel Deaconess Medical Center (Site 202-001), 330 Brookline Ave.
Boston, Massachusetts 02215
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Baystate Medical Center (Site 201-001), 759 Chestnut Street
Springfield, Massachusetts 01199
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

University of Michigan (Site 205-001), 1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Henry Ford Health System, Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd.
Detroit, Michigan 48202
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Minneapolis Heart Institute Foundation (Site 301-026), Abbott Northwestern Hospital, 920 E 28th St. #100
Minneapolis, Minnesota 55407
Contact:
If interested in partitipating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Hennepin Healthcare (Site 027-001), 701 Park Avenue
Minneapolis, Minnesota 55415
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Minneapolis VA Health Care System (Site 105-001), 1 Veterans Drive, Bldg 70
Minneapolis, Minnesota 55417
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

M Health Fairview University of Minnesota Medical Center (Site 112-001), 500 Harvard St. SE.
Minneapolis, Minnesota 55455
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

University of Mississippi Medical Center (Site 202-005), 2500 North State Street
Jackson, Mississippi 39216
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive
Lebanon, New Hampshire 03756
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Cooper University Hospital (Site 019-001), One Cooper Plaza
Camden, New Jersey 08103
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Lincoln Medical Center (New York Health and Hospitals/Lincoln) (Site 003-016), 234 E. 149th Street
Bronx, New York 10451
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road
Bronx, New York 10461
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street
Bronx, New York 10467
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

SUNY Downstate Medical Center (Site 033-001), 450 Clarkson Ave.
Brooklyn, New York 11203
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Maimonides Medical Center (Site 033-002), 4802 10th Avenue
Brooklyn, New York 11219
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Duke University Hospital (Site 301-006), 2301 Erwin Road
Durham, North Carolina 27710
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd
Winston-Salem, North Carolina 27157
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

University of Cincinnati Medical Center (Site 207-003), 234 Goodman Ave.
Cincinnati, Ohio 45219
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

University Hospitals Cleveland Medical Center (Site 108-001), 11100 Euclid Avenue
Cleveland, Ohio 44106
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Cleveland Clinic Fairview Hospital (Site 207-005), 18101 Lorain Avenue
Cleveland, Ohio 44111
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Cleveland Clinic Foundation (Site 207-001), 9500 Euclid Avenue
Cleveland, Ohio 44195
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Cleveland Clinic Marymount Hospital (Site 207-006), 12300 McCraken Road
Garfield Heights, Ohio 44125
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Oregon Health & Science University (Site 208-003), 3181 SW Sam Jackson Park Rd.
Portland, Oregon 97239-3098
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Portland VA Healthcare System (Site 074-024), 3710 SW. US Veterans Hospital Road
Portland, Oregon 97239
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

UPMC Magee-Womens Hospital (Site 209-003), 300 Halket Street
Pittsburgh, Pennsylvania 15213
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

UPMC Presbyterian Hospital (Site 209-001), 200 Lothrop Street
Pittsburgh, Pennsylvania 15213
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

UPMC Shadyside Hospital (Site 209-005), 5230 Centre Avenue
Pittsburgh, Pennsylvania 15232
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Rhode Island Hospital (Site 080-036), 593 Eddy Street
Providence, Rhode Island 02903
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

The Miriam Hospital (Site 080-039), 164 Summit Ave.
Providence, Rhode Island 02906
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

VA Providence Healthcare System (Site 074-025), 830 Chalkstone Ave.
Providence, Rhode Island 02908
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

Ralph H. Johnson VA Medical Center (Site 074-015), 109 Bee Street
Charleston, South Carolina 29401
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

MUSC Research Nexus Clinic (Site 210-002), 96 Jonathan Lucas St., CSB 214
Charleston, South Carolina 29425
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

MUSC Health Florence Medical Center (Site 210-006), 805 Pamplico Highway
Florence, South Carolina 29505
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

VA TVHS Nashville Campus (Site 074-022), 1310 24th Avenue South
Nashville, Tennessee 37212
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive
Nashville, Tennessee 37232
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

Hendrick Medical Center (Site 080-014), 1900 Pine Street
Abilene, Texas 79601
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

CHRISTUS Spohn Shoreline Hospital (Site 080-001), 600 Elizabeth Street
Corpus Christi, Texas 78404
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Parkland Health and Hospital Systems (Site 084-002), 5200 Harry Hines Blvd
Dallas, Texas 75235
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor
Dallas, Texas 75235
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave.
Dallas, Texas 75246
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd.
Houston, Texas 77030
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticowdc@insight-trials.org

Texas Heart Institute (Site 301-017), 6770 Bertner, MC4-266
Houston, Texas 77030
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

CHRISTUS Good Shepherd Medical Center (Site 080-031), 700 E. Marshall Ave.
Longview, Texas 75601
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street
Murray, Utah 84107
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

University of Utah Hospital (Site 211-002), 419 Wakara Way, Suite 207
Salt Lake City, Utah 84108
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

LDS Hospital (Site 211-004), 8th Ave. C Street
Salt Lake City, Utah 84143
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

University of Virginia Health Systems (Site 301-021), 1215 Lee Street
Charlottesville, Virginia 22903
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

Carilion Clinic (Site 080-018), 2001 Crystal Springs Ave., Suite 301
Roanoke, Virginia 24014
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticonih@insight-trials.org

Salem VA Medical Center (Site 074-014), 1970 Roanoke Blvd.
Salem, Virginia 24153
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticova@insight-trials.org

Swedish Hospital First Hill (Site 208-005), 747 Broadway
Seattle, Washington 98122
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticopetal@insight-trials.org

West Virginia University (Site 301-023), One Medical Center Drive
Morgantown, West Virginia 26506
Contact:
If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to
ticoctsn@insight-trials.org

More Details

NCT ID
NCT04501978
Status
Recruiting
Sponsor
University of Minnesota

Study Contact

If interested in participating in this study, please contact the appropriate site or
send email to
tico@insight-trials.org

Detailed Description

This is a master protocol to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression. The protocol is for a randomized, blinded, controlled platform study that allows investigational drugs to be added and dropped during the course of the study. This allows for efficient testing of new drugs against placebo and standard of care (SOC) treatment within the same study. When more than one drug is being tested at the same time, participants will be randomly allocated to treatments or placebo. Randomization will be stratified by study site pharmacy and disease severity. There are 2 disease severity strata: Participants without organ failure (severity stratum 1); and participants with organ failure (severity stratum 2). An independent Data and Safety Monitoring Board (DSMB) will regularly review interim analyses and summarize safety and efficacy outcomes. For investigational drugs with minimal pre-existing safety knowledge, the pace of enrollment with be initially restricted, and there will be an early review of safety data by the DSMB. For the study of each agent, at the outset of the trial, only participants in disease severity stratum 1 will be enrolled. This will continue until approximately 300 participants are enrolled and followed for 5 days. The exact number will vary according to the speed of enrollment and the timing of DSMB meetings. Prior to expanding enrollment to also include patients in disease severity stratum 2, safety will be evaluated and a pre-specified futility assessment by the DSMB will be carried out using 2 ordinal outcomes assessed at Day 5. Both ordinal outcomes are used to assess futility because it is currently unclear whether the investigational agents under study will primarily influence non-pulmonary outcomes, for which risk is increased with SARS-CoV-2 infection, in part, through mechanisms that may be different from those that influence pulmonary outcomes. For investigational agents passing this futility assessment, enrollment of participants will be expanded, seamlessly and without any data unblinding, to include participants in disease severity stratum 2 as well as those in disease severity stratum 1. Future interim analyses will be based on the primary endpoint of sustained recovery and will use pre-specified guidelines to determine early evidence of benefit, harm or futility for the investigational agent. Participants will be followed for 18 months following randomization. The international trials within this protocol will be conducted in several hundred clinical sites. Participating sites are affiliated with networks funded by the United States National Institutes of Health (NIH) and the US Department of Veterans Affairs.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.